<DOC>
	<DOCNO>NCT01288287</DOCNO>
	<brief_summary>To determine early clinical response 12 week Certolizumab Pegol ( CZP , Cimzia ® ) therapy adult Rheumatoid Arthritis ( RA ) patient predictor good long term clinical response 18 month compare lack clinical response 12 week .</brief_summary>
	<brief_title>Long Term Effects Early Response Certolizumab Pegol ( CZP , Cimzia® ) Rheumatoid Arthritis ( RA ) Patients</brief_title>
	<detailed_description>Clinical response assess percentage patient achieve reduction Baseline Disease Activity Score 28-joint count ( Erythrocyte Sedimentation Rate ) [ DAS28 ( ESR ) ] score great 1.2 point , consider minimum clinically important difference .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Informed consent sign date The patient consider capable prepare adhere study protocol procedures The patient prescribe CZP accord Summary Product Characteristics ( SmPC ) ( UK Eire ) National Institute Clinical Excellence ( NICE ) ( UK ) guideline anti tumor necrosis factor ( TNF ) α therapy Rheumatoid Arthritis ( RA ) . The patient screennegative tuberculosis The patient 18 year age The patient expose previously biological disease modify anti rheumatic drug ( DMARD ) agent . Patient previously participate study patient previously assign treatment study CZP another biological agent use treat RA . Patient participate another study within last 30 day Patient medical psychiatric condition , opinion physician , jeopardize would compromise patient 's ability adequately participate study Patient inadequate literacy understand complete questionnaire . Contraindications state SmPC Patient pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Certolizumab pegol</keyword>
	<keyword>Cimzia®</keyword>
</DOC>